Abbott Laboratories (ABT) Notes Payables (2009 - 2021)

Abbott Laboratories has disclosed Notes Payables across 13 years of filings, most recently posting $197.0 million for Q3 2021.

• Notes Payables for Q3 2021 came in at $197.0 million, down 5.29% year-over-year; the trailing twelve-month figure through Sep 2021 was $197.0 million (down 5.29% YoY), and the FY2020 annual result was $213.0 million, up 5.97% from the prior year.
• Notes Payables came in at $197.0 million for Q3 2021 at Abbott Laboratories, down from $199.0 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $341.0 million in Q2 2018 to a low of $197.0 million in Q3 2021.
• The 5-year median for Notes Payables is $205.0 million (2020), against an average of $213.6 million.
• Across the five-year window, Notes Payables sank 92.46% in 2017 and soared 56.42% in 2018, its largest moves.
• Abbott Laboratories' Notes Payables stood at $206.0 million in 2017, then slipped by 2.91% to $200.0 million in 2018, then increased by 0.5% to $201.0 million in 2019, then rose by 5.97% to $213.0 million in 2020, then decreased by 7.51% to $197.0 million in 2021.
• The last three Notes Payables figures came in at $197.0 million (Q3 2021), $199.0 million (Q2 2021), and $199.0 million (Q1 2021), per Business Quant data.